Cargando…
Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage
SUMMARY: We compared the patterns of osteoporosis medication prescribing between two provinces in Canada with different public drug coverage policies. Oral bisphosphonates were the primary drugs used, yet access to the second-generation oral bisphosphonates (alendronate, risedronate) was limited in...
Autores principales: | Cadarette, S. M., Carney, G., Baek, D., Gunraj, N., Paterson, J. M., Dormuth, C. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304053/ https://www.ncbi.nlm.nih.gov/pubmed/21901476 http://dx.doi.org/10.1007/s00198-011-1771-2 |
Ejemplares similares
-
Policy‐induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia
por: Fisher, Anat, et al.
Publicado: (2019) -
Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada
por: Carney, Greg, et al.
Publicado: (2022) -
Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada
por: Burden, A. M., et al.
Publicado: (2011) -
The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia
por: Ho, Harriet, et al.
Publicado: (2021) -
Trends in antihypertensive drug utilization in British Columbia, 2004–2019: a descriptive study
por: Kim, Jason D., et al.
Publicado: (2023)